Patatin‐like phospholipase 3 (rs738409) gene polymorphism is associated with increased liver enzymes in obese adolescents and metabolic syndrome in all ages

Mangge, Harald; Baumgartner, Bernhard; Zelzer, Sieglinde; Prüller, Florian; Schnedl, Wolfgang J.; Reininghaus, Eva; Haybaeck, Johannes; Lackner, Carolin; Stauber, Rudolf; Aigner, Elmar; Weghuber, Daniel

doi:10.1111/apt.13232

Cited by 37 publications

(38 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…NAFLD is the most common liver disease in children and adolescents (Table 2). Similarly to adult patients, NAFLD is associated with obesity and metabolic syndrome 27 and probably with elevated alanine aminotransferase (ALT) levels in blood and PNPLA3 polymorphisms 28 ( Figure 1) 29 . A recent analysis of the National Health and Examination Survey, including data from >12,000 12-19 year-old Americans, showed that NAFLD prevalence (with NAFLD defined as BMI > 85 th percentile and elevated ALT levels of >22.1 U/L for girls and >25.8 U/L for boys) more than doubled over the past two decades 27 .…”

Section: [H2] Children and Adolescentsmentioning

confidence: 99%

Nonalcoholic Fatty Liver Disease

Rinella

2015

JAMA

1,961

1,621

View full text Add to dashboard Cite

Section: [H2] Children and Adolescentsmentioning

confidence: 99%

Nonalcoholic Fatty Liver Disease

Rinella

2015

JAMA

1,961

1,621

View full text Add to dashboard Cite

“…PNPLA3 gene polymorphism is the most widely studied genetic determinant of NAFLD . The at‐risk GG genotype is associated with a 2‐ to 3‐fold increase in the risk of NAFLD.…”

Section: Discussionmentioning

confidence: 99%

“…PNPLA3 gene polymorphism is the most widely studied genetic determinant of NAFLD. [47][48][49] The at-risk GG genotype is associated with a 2-to 3-fold increase in the risk of NAFLD. In our study, the endotoxin biomarkers and fetuin-A level did not differ in subjects with different PNPLA3 genotypes.…”

Section: Discussionmentioning

confidence: 99%

Bacterial endotoxin and non‐alcoholic fatty liver disease in the general population: a prospective cohort study

Wong

Chan

et al. 2015

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…NAFLD is the most common liver disease in children and adolescents ( Table 2). Similarly to adult patients, NAFLD is associated with obesity and metabolic syndrome 27 and probably with elevated alanine aminotransferase (ALT) levels in blood and PNPLA3 polymorphisms 28 ( Figure 1) 29 . A recent analysis of the National Health and Examination Survey, including data from >12,000 [12][13][14][15][16][17][18][19] year-old Americans, showed that NAFLD prevalence (with NAFLD defined as BMI > 85 th percentile and elevated ALT levels of >22.1 U/L for girls and >25.8 U/L for boys) more than doubled over the past two decades 27 .…”

Section: [H2] Children and Adolescentsmentioning

confidence: 99%

Nonalcoholic Fatty Liver Disease

et al. 2020

View full text Add to dashboard Cite

Correspondence to: E.M.B. ebrunt@ wustl.edu Nonalcoholic fatty liver disease (NAFLD) is a liver disease characterized by excess fat accumulation in the hepatocytes (nonalcoholic fatty liver, NAFL); in up to 40% of individuals, there are additional findings of portal and lobular inflammation, and hepatocyte injury (nonalcoholic steatohepatitis, NASH). A small percent of patients will develop progressive fibrosis and cirrhosis. Hepatocellular carcinoma and cardiovascular complications are life-threatening co-morbidities of both NAFL and NASH. NAFLD is closely associated with insulin resistance; obesity and metabolic syndrome are common underlying factors. As a consequence, the prevalence of NAFLD is estimated to be 10-40% in adults worldwide, and it is the most common liver disease in children and adolescents in developed countries. Mechanistic insights into fat accumulation, subsequent hepatocyte injury, the role of the immune system and fibrosis as well as the role of the gut microbiome are unfolding, and genetic and epigenetic factors might explain the considerable inter-individual variation in disease phenotype, severity and progression. To date, no effective medical interventions exist that completely reverse the disease other than lifestyle changes, dietary alterations and possibly, bariatric surgery. However, several strategies targeting pathophysiological processes such as oversupply of fatty acids to the liver, cell injury and inflammation are currently under investigation. Diagnosis of NAFLD, and detecting the lesions of NASH, still depend on the gold-standard but invasive liver biopsy. Several non-invasive strategies are being validated to replace or complement biopsies, especially for follow-up monitoring.[H3] The United States and Europe. NAFLD is currently the most common cause of abnormal liver function tests in Western countries. According to population studies using ultrasonography or CT imaging, the prevalence of NAFLD is in the range 20-50% (Table 1). 10-13 NAFLD prevalence varies markedly between ethnic groups. An urban population study in the United States using protonmagnetic resonance spectroscopy ( 1 H-MRS) showed that the prevalence of hepatic steatosis was 45% in Hispanic, 33% in white, and 24% in black populations. 14 These variations can be explained by differences in lifestyle, prevalence of metabolic syndrome and genetics, such as polymorphism of the patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene, which encodes a lipase that mediates triacylglycerol hydrolysis in adipocytes. (Figure 1). NAFLD is strongly associated with metabolic disorders. Not surprisingly, fatty liver has been reported in 40-80% of patients with type 2 diabetes mellitus and 30-90% of obese patients. 15,16 Since imaging can only detect fatty liver but not necroinflammation or fibrosis, the prevalence of NASH and the related liver fibrosis in the population is unclear. Histological analyses suggest that 6-55% of patients with NAFLD have NASH, depending on the patient inclusion criteria and the def...

show abstract

Patatin‐like phospholipase 3 (rs738409) gene polymorphism is associated with increased liver enzymes in obese adolescents and metabolic syndrome in all ages

Cited by 37 publications

References 32 publications

Nonalcoholic Fatty Liver Disease

Nonalcoholic Fatty Liver Disease

Bacterial endotoxin and non‐alcoholic fatty liver disease in the general population: a prospective cohort study

Nonalcoholic Fatty Liver Disease

Contact Info

Product

Resources

About